Philips and Yale expand research deal

Royal Philips (NYSE:PHG) said today it expanded its master research agreement with Yale School of Medicine to include a new research program looking to develop innovations in interventional oncology. The multi-year cancer research program aims to explore new concepts in image-guided therapies, diagnostic imaging and informatics, Philips said, and will engage with multiple research groups at Yale. “Over the past few years there have been significant developments in image-guided therapy to locally treat tumors, with the result that interventional oncology procedure volumes have grown rapidly. However, the biggest remaining challenge is that it is difficult to predict the effectiveness of the procedure. Together with Philips, we are embarking on a new multi-year research program with the aim to redefine and standardize this type of minimally-invasive treatment to achieve more predictable and better controlled procedure outcomes, and ultimately enhanced patient care,” research program lead Jeff Geschwind said in a press release. A team of clinical scientists from Philips will operate with Geschwild’s team at Yale in a recently established facility seeking to shift research results into innovations for patient care, the company said. “We are on a mission to enhance existing interventional oncology procedures and enable new ones that offer predictable and effective minimally invasive options for treating cancerous lesions. Our new collaboration wit...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diagnostics Oncology Research & Development Royal Philips Source Type: news

Related Links:

A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
In this study, the gut microbiota of 30 LC patients and 30 healthy controls were examined via next-generation sequencing of 16S rRNA and analyzed for diversity and biomarkers. We found that there was no decrease in significant microbial diversity (alpha diversity) in LC patients compared to controls (P observed = 0.1422), while the composition (beta diversity) differed significantly between patients and controls (phylum [stress = 0.153], class [stress = 0.16], order [stress = 0.146], family [stress = 0.153]). Controls had a higher abundance of the bacterial phylum Actinobacteria and genus Bifidobacterium, while patients wi...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Org. Biomol. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9OB00651F, PaperAgata Campisi, Maria Assunta Chiacchio, Laura Legnani, Paola Bottino, Giuseppe Lanza, Daniela Iannazzo, Lucia Veltri, Salvatore V. Giofr è, Roberto ROMEO A series of 2,3,4-triaryl-substituted 1,2,4-oxadiazole-5-ones have been prepared as fixed-ring analogues of tamoxifen (TAM), a drug inhibitor of Estradiol Receptor (ER) used in breast cancer therapy, by an efficient synthetic... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Organic and Biomolecular Chemistry - Category: Molecular Biology Authors: Source Type: research
When a prostate cancer staging exam is needed, clinicians at one Australian...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI: Early prostate cancer therapy extends lives
Source: Headlines - Category: Radiology Source Type: news
(Stand Up To Cancer) Pancreatic Cancer Collective-funded research (Lustgarten Foundation and Stand Up To Cancer) from Dr. Tony Hunter (Salk Institute) and the SU2C-CRUK-Lustgarten Pancreatic Cancer Dream Team has found the presence of a key protein (Leukemia Inhibitory Factor or LIF) in PDAC microenvironment may be an exploitable treatment target to slow tumor progression or metastasis and may lead to the development of new targeted strategies for pancreatic cancer therapy.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
(University of Nebraska-Lincoln) A new study in Nature has identified a potential strategy for treating multiple forms of cancerous tumors: targeting a protein that maliciously rewires immune cells and impedes cancer therapies. The researchers showed that inhibiting the protein with an existing compound helped slow or even reject tumors stemming from four cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
LangmuirDOI: 10.1021/acs.langmuir.9b00607
Source: Langmuir - Category: Chemistry Authors: Source Type: research
Publication date: Available online 16 April 2019Source: International Journal of PharmaceuticsAuthor(s): Jianhua Zhang, Jun Huang, Keqing Huang, Jiayuan Zhang, Zhengqiu Li, Tianbao Zhao, Jun WuAbstractTo development biomimetic strategy for enhanced cancer therapy, the paclitaxel loaded egg white/sodium alginate nanoparticles were prepared by electronic spray method. Their appearance and particle size were observed by transmission electron microscope and particle size analyzer. The drug release behavior of nanoparticles was determined by high performance liquid chromatography (HPLC). The toxicity, morphology and interaction...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: August 2019Source: Biomedicine &Pharmacotherapy, Volume 116Author(s): Badriya Baig, Sulafa Abdel Halim, Aaminah Farrukh, Yaser Greish, Amr AminAbstractCancer continues to be the leading cause of death worldwide. Hepatocellular carcinoma (HCC), a prominent form of liver cancer, is the second leading cause of cancer-related deaths, thanks to the lack of efficient diagnostic tools and consequently late diagnosis and to the scarce of available suitable treatments. Thus, novel approaches to treat HCC are in demand. The fast-growing field of nanotechnology offers infinite possibilities to design materials i...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human diseases. FI...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Liver | Medical Devices | Urology & Nephrology | Yale